This presentation will outline the safety and bioactivity of KSI-501ABC in patients with diabetic macular edema (DME).
Kodiak Sciences Inc. will share first time results of the KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 virtual meeting. KSI-501ABC is the second product candidate built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform.
In the press release, J. Pablo Velazquez-Martin, MD, Senior Vice President of Clinical Research and Development at Kodiak Sciences noted that the results the company plans to share support further research. He said, "we look forward to sharing for the first time the results of our Phase 1 study of KSI-501ABC, our anti-IL-6 antibody and VEGF-trap bispecific therapeutic candidate in its antibody biopolymer conjugate form. The data being presented will outline the safety and bioactivity of KSI-501ABC in patients with diabetic macular edema (DME), a disease known to have high levels of cytokine-mediated microvascular inflammation in addition to VEGF-mediated fluid and leakage. We believe these early results support further clinical development of the KSI-501 program.”
The presentation details are as follows:
KSI-501 Bispecific Anti-VEGF Anti-IL-6 Antibody Biopolymer Conjugate: First Time Results of the Multiple Ascending Dose Phase 1 Study
The company has said that it plans to post the presentation slides on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ at the beginning of the presentation.